Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pharmacyte Biotech, Inc. on November 7, 2019, regarding events occurring on that date. The company is incorporated in Nevada and maintains its principal executive offices in Laguna Hills, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is an amendment to the Company's Articles of Incorporation, confirmed by the Nevada Secretary of State on November 7, 2019, with an effective date of October 31, 2019. The amendment increased the total authorized capital stock from 1,500,000,000 shares to 2,500,000,000 shares. The new capital structure consists of:
- Common Stock: 2,490,000,000 authorized shares with a par value of $0.0001.
- Preferred Stock: 10,000,000 authorized shares with a par value of $0.0001.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the amendment to the Articles of Incorporation and includes the Certificate of Amendment as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the effective date of the capital stock increase (October 31, 2019).
- Confirm the new total authorized share count of 2.5 billion shares.
- Review the attached Exhibit 3.1 for the complete terms and conditions of the Certificate of Amendment.
- Note that no financial data or operational updates are included in this specific filing.